Immunitybio, Inc. quarterly report, Q1 FY2020

Business context and reporting period

This is NantKwest, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2020. The request metadata names ImmunityBio, Inc., but the filing identifies NantKwest as the registrant; ImmunityBio is described as a related-party affiliate. NantKwest is a clinical-stage immunotherapy company developing natural-killer-cell therapies for cancer and viral diseases. It reported no product sales.

Financial results and liquidity

At March 31, 2020, cash and cash equivalents were $17.0 million and available-for-sale marketable debt securities were $23.3 million, for approximately $40.2 million in cash and investments. Restricted cash was $0.2 million. Current assets of $44.1 million exceeded current liabilities of $14.2 million. Total liabilities were $24.4 million, including operating lease liabilities; the filing does not report conventional borrowings. Total assets were $127.0 million, and stockholders’ equity was $102.6 million. Gross margin is not meaningful given the immaterial revenue and absence of product sales.

Material changes versus the prior comparable period

• Net loss increased by $0.5 million year over year, while operating expenses rose 1% to $18.6 million.
• R&D expense increased $0.6 million, primarily due to manufacturing-facility validation and qualification, depreciation, shared services, preclinical work, and cell-bank costs; lower amortization and clinical-site costs partly offset the increases.
• SG&A declined $0.4 million, mainly from lower stock-based compensation and travel, partly offset by higher legal, insurance, and consulting expenses.
• Operating cash use improved by $0.5 million. Investing activities provided $14.2 million, largely from security maturities and sales. Financing activities used $0.1 million; unlike Q1 2019, there were no material proceeds from insider option and warrant exercises.
• Marketable debt securities declined from $37.6 million at December 31, 2019 to $23.3 million at March 31, 2020, as securities matured or were sold. The quarter-end balance sheet classifies all remaining securities as current.

Outlook, commentary, risks, and unusual items

• Management expects significant expenses and operating losses to continue as development advances, and does not expect product revenue for at least several years, if ever.
• The filing says existing cash, cash equivalents and investments, together with the ability to borrow from affiliated entities, are expected to fund operations and capital needs for at least 12 months following issuance of the financial statements. This expectation depends on assumptions and the Chairman and CEO’s stated intent and ability to provide support; there is no committed external funding source. Additional financing may be needed and may dilute shareholders or require program reductions.
• COVID-19 had not materially affected Q1 results, but management expected slower enrollment and longer trial timelines, potentially delaying commercialization. Supply interruptions, site restrictions, regulatory delays, and capital-market disruption were identified as risks. Office-based staff began working remotely in mid-March while essential laboratory and manufacturing operations continued.
• The filing reported FDA clearance for the QUILT 88 study of PD-L1.t-haNK, N-803 and aldoxorubicin in pancreatic cancer. It also anticipated regulatory clearance during Q2 2020 for two COVID-19 studies; these were expectations, not reported approvals or completed trials.
• In January 2020, NantKwest and ImmunityBio entered a cost-sharing arrangement for a Merkel cell carcinoma study. NantKwest recorded $0.1 million of related costs as a reduction in R&D expense and a $0.1 million receivable from ImmunityBio.
• Related-party arrangements include shared services, facilities, clinical-trial services, and study-drug supply. The filing highlights potential dependence on affiliates and conflicts of interest. NantKwest also reported a $9.3 million investment in Viracta, with no impairment identified at quarter-end.
• Management reported no current legal proceeding it believed likely to have a material adverse effect. Earlier securities litigation was settled in 2019 for $12.0 million, mostly funded by insurers. Disclosure controls were assessed as effective at the reasonable-assurance level, with no material change in internal control reported for the quarter.

Important facts for investors to verify

• Confirm the issuer: this filing is for NantKwest, not ImmunityBio, despite the request metadata; review any subsequent corporate or reporting changes separately.
• Track cash burn, security maturities, affiliate borrowing or support, and the assumptions behind the stated 12-month funding outlook.
• Monitor clinical enrollment, regulatory milestones, and any COVID-19-related trial or supply-chain delays; distinguish anticipated milestones from achieved ones.
• Review the terms, balances, and governance oversight of related-party services, leases, clinical work, and cost-sharing arrangements.
• Assess whether manufacturing scale, trial results, regulatory approval, and future financing can support eventual commercialization; the filing reports minimal licensing revenue and no product sales.